Get the Stockscreener App
5.25
2.34%
0.12
Polypid Ltd stock is traded at $5.25, with a volume of 103.55K.
It is up +2.34% in the last 24 hours and down -0.38% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$5.13
Open:
$5.14
24h Volume:
103.55K
Relative Volume:
0.87
Market Cap:
$106.64M
Revenue:
Net Income/Loss:
$-33.63M
P/E Ratio:
-2.7452
EPS:
-1.9124
Net Cash Flow:
$-47.63M
1W Performance:
+11.23%
1M Performance:
-0.38%
6M Performance:
+13.15%
1Y Performance:
+52.62%
1-Day Range:
$5.11
$5.25
1-Week Range:
$4.77
$5.25
52-Week Range:
$3.14
$5.73
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
5.25 | 106.64M | 0 | -33.63M | -47.63M | -1.9124 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
PolyPid to Present D-PLEX₁₀₀ Microbiology Data at IDWeek 2026 - GlobeNewswire Inc.
PolyPid Ltd.Ordinary Shares (Nasdaq:PYPD) Stock Quote - The Chronicle-Journal
PYPD Q2 2026 Earnings: PolyPid Posts Narrower-Than-Expected Loss With No Reported RevenueFinancial Data - dars.gov.et
PolyPid (PYPD): Will The November FDA Decision Propel The Stock? - RTTNews
PolyPid (PYPD) Stock: Finishes 0.59% Up at $5.13 in the Current Update; Trading Range - vinanet.vn
PolyPid (PYPD) Stock: Finishes 0.59% Up at $5.13 in the Current Update; Trading Range - dars.gov.et
PolyPid (PYPD) Stock: Finishes 0.59% Up at $5.13 in the Current Update; Trading Range - dars.gov.et
PolyPid (PYPD) Stock: Finishes 0.59% Up at $5.13 in the Current Update; Trading Range - www.dars.gov.et
PolyPid (PYPD) Q2 2026 Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Closing Reaction: Shares Close 1.40% Higher in Latest TradingRetail Earnings Report - vinanet.vn
PolyPid | 3: Initial statement of beneficial ownership of securities- Warshavsky Ori - Moomoo
PolyPid | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
PolyPid (PYPD) Q2 2026 Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Closing Reaction - dars.gov.et
PolyPid (PYPD) Q2 2026 Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Closing Reaction: Shares Close 1.40% Higher in Latest TradingEarnings Season Preview - dars.gov.et
AIGH Capital Management LLC Purchases Shares of 1,504,741 PolyPid Ltd. $PYPD - MarketBeat
PolyPid Ltd (PYPD) Stock News Today - TradingKey
PolyPid Ltd. (PYPD) Holds Near $4.75 as Clinical-Stage Biotech Navigates Key Support ZoneCall Resistance - vinanet.vn
Conferencia de resultados del 2T de 2026 de PolyPid (PYPD): revisión prioritaria de D-PLEX100 y acuerdo con Azurity - TradingKey
What is HC Wainwright's Forecast for PolyPid Q3 Earnings? - MarketBeat
PolyPid (PYPD) Earnings Call zum 2. Quartal 2026: Prioritäre Prüfung für D-PLEX100 und Azurity-Deal - TradingKey
PolyPid Ltd. (PYPD) Holds Near $4.75 as Clinical-Stage Biotech Navigates Key Support ZoneRisk Reversal - dars.gov.et
LanzaTech Global Warrant (LNZAW) Holds Steady at $0.02 as Support and Resistance ConvergeExtension Target - dars.gov.et
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
PolyPid (PYPD) investors disclose up to 13.4% beneficial stake via complex structure - Stock Titan
PolyPid Ltd. (PYPD) Slips 2.27% to $4.73 as Shares Test Key Support ZoneBollinger Walk - dars.gov.et
PolyPid Ltd. (PYPD) Slips 2.27% to $4.73 as Shares Test Key Support ZoneWyckoff Distribution - vinanet.vn
HC Wainwright Issues Negative Estimate for PolyPid Earnings - MarketBeat
PolyPid Ltd. (PYPD) Slips 2.27% to $4.73 as Shares Test Key Support ZoneWedge Breakout - dars.gov.et
PolyPid Ltd. (PYPD) Slips 2.27% to $4.73 as Shares Test Key Support ZoneGEX Level - careplusvn.com
PolyPid Ltd. (PYPD) Slips 2.27% to $4.73 as Shares Test Key Support ZoneDaily Profile - https://www.dars.gov.et/
PolyPid Ltd. (PYPD) Slips 2.27% to $4.73 as Shares Test Key Support ZoneWedge Breakout - dars.gov.et
PolyPid Earnings Call: Priority Review, Big Azurity Deal - TipRanks
PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ... - Yahoo Finance
PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline - TipRanks
PolyPid Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
PolyPid (PYPD) secures $30M Azurity payments but flags going concern risk - Stock Titan
Transcript : PolyPid Ltd., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Rosalind entities (PYPD) report 9.9% PolyPid stake, with 4.56M warrant shares blocked at 9.99% - Stock Titan
PolyPid Releases Q2 2026 Financial Results - AlphaStreet
PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
PolyPid Q2 Earnings Call Highlights - NewsBreak: Local News & Alerts
PolyPid Q2 Earnings Call Highlights - MarketBeat
PolyPid Q2 Earnings Call Highlights - MarketBeat
PolyPid Q2 Earnings Call Highlights - TradingView
PolyPid Q2 losses narrow 55%, FDA accepts D-PLEX100 NDA - scanx.trade
Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket - Investing.com Australia
Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket - Investing.com India
Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket - Investing.com Canada
Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket - Investing.com
PolyPid Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket - Investing.com
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.09%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):